on PREDILIFE (EPA:ALPRE)
Major validation of the MammoRisk strategy against breast cancer
PREDILIFE announces a significant advance in breast cancer screening. The results of the WISDOM study, published in JAMA, confirm the effectiveness of risk-based screening strategies. This randomized study included more than 28,000 women aged 40 to 74. It compared standard annual screening with personalized screening based on individual risk.
Advanced-stage breast cancer decreased by 37.5% in the group receiving personalized screening. In Europe, the approach is being evaluated in the MyPeBS study of 53,000 women, using Predilife's MammoRisk test. MammoRisk, whose performance has been validated in the UK, is based on a US model of nearly one million women.
These results reinforce PREDILIFE's commitment to deploying these personalized approaches in Europe and the United States.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PREDILIFE news